Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2024 09:30 ET | Source: VIVUS LLC

VIVUS Shares Significant Regulatory Update on QSYMIA®

- Postmarketing requirement fulfilled based on data demonstrating QYSMIA® reduces blood pressure - CAMPBELL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- VIVUS announced today that the U.S. Food and...
October 23, 2024 09:00 ET | Source: VIVUS LLC

VIVUS Announces Label Update for QSYMIA®

– QSYMIA® is the leading once-daily oral branded, weight-management medication – – First head-to-head randomized placebo-controlled study of QSYMIA® and phentermine demonstrating reductions in...
October 07, 2024 09:00 ET | Source: VIVUS LLC

VIVUS Announces Commercialization of QSIVA® in Sweden, Denmark, Finland, Iceland, Norway, and Poland

AMSTERDAM, Oct. 07, 2024 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, today announced the availability of QSIVA® (phentermine and topiramate modified-release) in Sweden, Denmark,...
May 30, 2024 09:00 ET | Source: VIVUS LLC

Clinical Data Published at ASCO Support the Potential of VIVUS’ PANCREAZE® to Stabilize Weight and Improve Gastrointestinal Outputs in Patients with Pancreatic Cancer

CAMPBELL, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing...
April 22, 2024 09:00 ET | Source: VIVUS LLC

VIVUS Announces it will Provide Telehealth to Patients through an Enhanced 'Engage' Program in Collaboration with UpScriptHealth

Collaboration will deliver a seamless telehealth experience, providing patients with immediate access to QSYMIA®, a chronic weight loss medication, enhancing their healthcare journey CAMPBELL,...
January 08, 2024 09:00 ET | Source: VIVUS LLC

VIVUS Provides Update on Pipeline and Program Milestones

CAMPBELL, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing...
November 28, 2023 09:00 ET | Source: VIVUS LLC

New Clinical Data Demonstrate that QSYMIA®, the Leading Once-Daily Oral Weight-Management Medication, Reduces Blood Pressure

CAMPBELL, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing...
May 17, 2023 03:30 ET | Source: VIVUS LLC

VIVUS’ QSIVA in Combination with a Digital Lifestyle Intervention Leads to Significant Weight Loss and Decreased Cardiovascular Risk in Patients with Obesity

— Poster presented at the 30th European Congress on Obesity (ECO 2023) shows addition of QSIVA provides benefits compared with Digital Lifestyle Intervention (DLI) alone in improving health outcomes...
January 10, 2023 09:00 ET | Source: VIVUS LLC

VIVUS Announces Key Management Updates to Support Global Expansion Strategy

CAMPBELL, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- VIVUS LLC today announced the promotion of Santosh T. Varghese, MD, to President VIVUS Global Pharmaceutical Development. With more than 25 years...
July 20, 2022 09:00 ET | Source: VIVUS LLC

FDA Approves QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-17

CAMPBELL, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- VIVUS LLC today announced that the U.S. Food and Drug Administration (FDA) approved QSYMIA (phentermine and topiramate extended-release capsules)...